STOCK TITAN

Harrow Inc - HROW STOCK NEWS

Welcome to our dedicated news page for Harrow (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Harrow's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Harrow's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.86%
Tags
fda approval
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.63%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.91%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.3%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.39%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
earnings
Harrow Inc

Nasdaq:HROW

HROW Rankings

HROW Stock Data

450.17M
26.42M
14.59%
66.11%
15.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Nashville

About HROW

harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas